Sarepta Therapeutics, Inc. (SRPT) to Release Earnings on Wednesday
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will release its earnings data after the market closes on Wednesday, October 25th. Analysts expect Sarepta Therapeutics to post earnings of ($0.91) per share for the quarter.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. The company’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.19) earnings per share. On average, analysts expect Sarepta Therapeutics to post $-1.16 EPS for the current fiscal year and $-1.63 EPS for the next fiscal year.
Shares of Sarepta Therapeutics, Inc. (SRPT) opened at 51.72 on Wednesday. Sarepta Therapeutics, Inc. has a 1-year low of $26.26 and a 1-year high of $55.02. The company’s market capitalization is $3.33 billion. The stock’s 50 day moving average price is $45.98 and its 200-day moving average price is $37.19.
A number of research analysts have weighed in on SRPT shares. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $71.00 target price on shares of Sarepta Therapeutics in a report on Friday, October 6th. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $64.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. Leerink Swann reissued a “buy” rating and issued a $60.00 target price (up previously from $52.00) on shares of Sarepta Therapeutics in a report on Tuesday, July 18th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $50.00 target price on shares of Sarepta Therapeutics in a report on Thursday, July 20th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $64.34.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/18/sarepta-therapeutics-inc-srpt-to-release-earnings-on-wednesday.html.
In other news, SVP Alexander Cumbo sold 5,918 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the transaction, the senior vice president now directly owns 22,793 shares in the company, valued at approximately $934,513. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Shamim Ruff sold 12,138 shares of Sarepta Therapeutics stock in a transaction on Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the transaction, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,556 shares of company stock valued at $3,799,208. 9.60% of the stock is currently owned by corporate insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.